However, statins recovered cartilage formation in the TD1 disease model by mitigating the amount of phosphorylated mitogen-activated protein kinase (MAPK), which is downstream of the FGFR3 signaling pathway. Here, FGFR3 is linked to thanatophoric dysplasia type 1.